Peptide Therapy in Philadelphia
Medically reviewed by Charlie Seltzer, MD, CSCS · Updated October 2026
For years, peptides like BPC-157 and TB-500 were bought online as "research chemicals," with no doctor, no testing and no way to know what was in the vial. Demand exploded anyway. On October 28, 2026, HHS cleared licensed compounders to prepare six of them for individual patients under strict quality rules. Now you can get them the right way: evaluated and prescribed by a physician, compounded to pharmacy standards, and monitored as you go.
The six peptides
| Peptide | Studied for | How it's taken |
|---|---|---|
| BPC-157 | Tendon, ligament, joint and gut repair | Injection, oral or topical |
| TB-500 | Soft-tissue recovery; pairs with BPC-157 | Injection |
| MOTS-c | Insulin sensitivity, fat loss, muscle metabolism | Injection |
| Epitalon | Sleep, circadian rhythm, healthy aging | Injection, intermittent courses |
| Semax | Focus, memory, stress resilience, migraine | Nasal spray |
| KPV | Gut and skin inflammation | Oral or topical |
The honest evidence scorecard
Most peptide sites skip this part. We don't.
| Peptide | Human data | Animal data | Main safety flag |
|---|---|---|---|
| BPC-157 | Small pilot studies | Strong | Theoretical concern with cancer history |
| TB-500 | None for the fragment | Moderate | No human safety data |
| MOTS-c | None as a treatment yet | Strong | No human safety data |
| Epitalon | Limited, mostly Russian | Moderate | FDA flagged possible cancer risk |
| Semax | Russian clinical use | Moderate | Possible bleeding risk; stimulant interaction |
| KPV | None | Moderate | No human data; oral and topical only |
FDA's drug reviewers recommended against all six, citing thin human data and the risk of immune reactions to injected peptides. HHS sided with its outside advisory panel instead, describing the concerns as gaps in information rather than observed harm. For TB-500, HHS called the risk "inferential rather than observed." For KPV, "an absence of information rather than an observed signal." That's why every product now comes with strict testing and side-effect reporting.
Gray market vs. Dr. Seltzer
| Online "research" peptides | Dr. Seltzer Lifestyle Medicine | |
|---|---|---|
| Source | Often unknown, frequently overseas | FDA-registered, CGMP ingredient manufacturer |
| Testing | Rarely verified; vials have tested underdosed or contaminated | Identity, purity, potency and contaminant testing |
| Dosing | Forum guesswork | Set by a physician for you |
| Screening | None | Full medical evaluation first |
| Monitoring | None | Physician follow-up throughout |
| Legal status | Sold "not for human use" | Prescribed and compounded under federal policy |
The new rules in plain English
It's not FDA approval. Under federal law, these six peptides still don't qualify as standard compounding ingredients. HHS is using "enforcement discretion": it won't take action against compounding that follows its rules. HHS put the six on a separate "503A Interim Access List," and the policy runs for each peptide until FDA issues a final rule on it. HHS calls the policy non-binding and says it can revisit it if a safety or quality problem appears.
Who can provide them. State-licensed 503A compounding pharmacies, federal facilities and licensed physicians, always on a patient-specific prescription. Larger 503B outsourcing facilities are not covered, and telehealth companies must fill through a 503A pharmacy.
The ten conditions. HHS requires compounders to meet all ten of its "appropriate safeguards." The ones that matter most to you as a patient:
- The exact peptide, in one exact form. Acetate salt for BPC-157, TB-500, MOTS-c, Epitalon and KPV; free base for Semax.
- Approved routes only. Semax is nasal only, KPV is oral or topical only, and Epitalon is given in intermittent courses.
- One peptide per product. No premixed stacks. A patient on BPC-157 and TB-500 gets two separate products.
- A full certificate of analysis on every lot, from the original FDA-registered, CGMP-compliant manufacturer. It covers identity, purity, potency and contaminants such as endotoxins, leftover manufacturing chemicals and nitrosamines. A middleman can't just pass along someone else's paperwork.
- Simple delivery only. Injectables ship with a standard FDA-cleared syringe, never pens or auto-injectors.
- Proof oral forms actually absorb. HHS notes oral peptide absorption is difficult, so oral products need documentation that the formulation works in humans.
- Mandatory safety reporting. Every serious side effect goes to FDA's MedWatch and to state authorities, even if no one thinks the peptide caused it. Labels must tell patients how to report problems.
State rules still apply. HHS's policy doesn't bind state pharmacy boards, and some states, such as Ohio, still restrict peptides like BPC-157.
Who should not take peptides
- Anyone pregnant or breastfeeding, or under 18
- Anyone with an active cancer or a history of cancer (especially BPC-157, TB-500 and Epitalon)
- Anyone on blood thinners (Semax)
- Competitive athletes who are drug-tested: BPC-157 and TB-500 are banned by the World Anti-Doping Agency
Policy updates
- October 27–28, 2026: HHS posts and announces an interim enforcement discretion policy (Federal Register document 2026-22192), signed by Secretary Robert F. Kennedy Jr., opening compounded access to BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV under ten conditions.
- July 2026: FDA's Pharmacy Compounding Advisory Committee spends two days reviewing seven peptides and narrowly votes for six. The seventh, emideltide, a sleep and pain peptide, is rejected. FDA's own scientists had recommended against all seven.
- April 2026: FDA unexpectedly moves the seven peptides off its "Category 2" high-risk list, clearing the way for the review.
- 2023: FDA places these peptides, along with 13 others, on Category 2, effectively barring pharmacies from compounding them and pushing demand to the gray market.
We update this page as the rules change.
Why Dr. Seltzer
Dr. Charlie Seltzer is a physician, a certified strength and conditioning specialist, and a national-level bodybuilding champion. The peptide world grew up in his world. He knows what athletes and high performers have been using, and he knows the medicine behind it. Peptides fit alongside his weight loss, personal training and sports performance programs.
Frequently asked questions
Are peptides legal now?
Six specific peptides are, when prescribed by a physician and compounded under HHS's October 2026 policy. They are still not FDA-approved.
Is this the same as FDA approval?
No. FDA approval requires large human trials. This policy lets licensed pharmacies compound six peptides under strict quality rules while FDA decides whether to add them permanently to the compounding list.
Can a doctor prescribe BPC-157?
Yes. A licensed physician can prescribe BPC-157 and the other five for individual patients.
Can I get a BPC-157 and TB-500 stack?
Yes, as two separate prescriptions. Premixed blends aren't covered.
Why can't I get a peptide pen?
HHS limits delivery to a standard FDA-cleared syringe. It considers pens and auto-injectors an added risk for these products.
Can BPC-157 be taken by mouth?
Oral BPC-157 is allowed, but HHS requires documentation that the oral formulation actually absorbs in humans. Dr. Seltzer will recommend the right form for your goal.
How long will this policy last?
For each peptide, until FDA finishes rulemaking on it, which could take a year or more. We'll update this page as it changes.
Do you offer virtual visits?
Yes. Dr. Seltzer sees patients in Center City and virtually.
Where is the office?
1429 Walnut Street, Suite 401, Philadelphia, PA 19102.
Start with a consultation
Official sources
- HHS 503A peptide enforcement discretion policy (Appendix B)
- Federal Register notice 2026-22192
- FDA Pharmacy Compounding Advisory Committee
- Report a side effect to FDA MedWatch
The peptides on this page are compounded drug products and are not FDA-approved. They are available by prescription under the U.S. Department of Health and Human Services' 2026 enforcement discretion policy for 503A compounding. Individual results vary.